Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
Want to see KLRS full AI Analyst Report?
KLRS Stock Chart & Stats
$6.32
--
Market closed
$6.32
--
Day’s Range― - ―
52-Week Range$2.14 - $11.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)136.22K
Market Cap
$115.03M
Enterprise Value$65.55M
Total Cash (Recent Filing)$97.22M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 19, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding23,792,278
10 Day Avg. Volume189,046
30 Day Avg. Volume136,224
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-2.98
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.28K
Enterprise Value/Ebitda-1.43
Forecast
1Y Price Target
$15.75Price Target Upside149.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Cash Runway From $50M FinancingThe company strengthened its balance sheet via a $50M private placement and explicitly guided funding into Q4 2027. This durable funding visibility materially reduces near-term financing risk and supports advancing TH103 toward Phase 3, improving execution capacity over the next 2–3 years.
Low Financial Leverage And Equity CushionBalance sheet shows minimal debt relative to equity, indicating limited leverage and financial flexibility. A low-debt profile reduces solvency risk and preserves borrowing capacity, which is important for a pre-revenue biotech that will rely on financing to fund clinical programs.
Lead Asset With Clear Clinical PathTH103 targets a large, growing retinal market and is positioned as a dual-action anti-VEGF with Phase 1a validation and plans toward Phase 3. A differentiated late-stage program offers durable upside if clinical and regulatory milestones are met, underpinning long-term value creation.
Bears Say
Pre-revenue With Sustained Large LossesKLRS remains pre-revenue and incurred substantial net losses (~$43–44M in recent periods). Without product sales, profitability is structurally negative, meaning the company cannot self-fund operations and remains dependent on successful clinical outcomes and external capital over the medium term.
High Operating Cash BurnOperating cash flow was deeply negative (~-$48.9M TTM), reflecting sizable R&D and operating spend. Though burn improved versus prior years, this magnitude requires ongoing financing and creates dilution and execution risk if clinical timelines slip or fundraising conditions deteriorate.
Finance Leadership TransitionThe CFO resigned and the Chief Accounting Officer will assume principal financial officer duties. During a critical funding and late-stage development period, even an internal continuity move can introduce short-term governance and execution risks around fundraising, financial reporting, and investor relations.
Kalaris Therapeutics News
KLRS FAQ
What was Kalaris Therapeutics’s price range in the past 12 months?
Kalaris Therapeutics lowest stock price was $2.14 and its highest was $11.88 in the past 12 months.
What is Kalaris Therapeutics’s market cap?
Kalaris Therapeutics’s market cap is $115.03M.
When is Kalaris Therapeutics’s upcoming earnings report date?
Kalaris Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 78 days.
How were Kalaris Therapeutics’s earnings last quarter?
Kalaris Therapeutics released its earnings results on May 12, 2026. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.523 by $0.063.
Is Kalaris Therapeutics overvalued?
According to Wall Street analysts Kalaris Therapeutics’s price is currently Undervalued.
Does Kalaris Therapeutics pay dividends?
Kalaris Therapeutics does not currently pay dividends.
What is Kalaris Therapeutics’s EPS estimate?
Kalaris Therapeutics’s EPS estimate is -0.47.
How many shares outstanding does Kalaris Therapeutics have?
Kalaris Therapeutics has 23,792,278 shares outstanding.
What happened to Kalaris Therapeutics’s price movement after its last earnings report?
Kalaris Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.523. Following the earnings report the stock price went up 1.268%.
Which hedge fund is a major shareholder of Kalaris Therapeutics?
Currently, no hedge funds are holding shares in KLRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kalaris Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (149.21% Upside)
$15.75 (149.21% Upside)
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 9.8%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.99%
12-Months-Change
Fundamentals
Return on Equity
-72.78%
Trailing 12-Months
Asset Growth
6.51%
Trailing 12-Months
Company Description
Kalaris Therapeutics
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
KLRS Stock 12 Month Forecast
Average Price Target
$15.75
▲(149.21% Upside)
Technical Analysis
Coherus Biosciences
―
Nektar Therapeutics
―
Cellectis SA
―
Seres Therapeutics
―
Kodiak Sciences
―
Ownership Overview
54.44% Insiders
1.98% Mutual Funds
4.37% Other Institutional Investors
38.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---